Pharmaceutical Industry

Personal Genome Diagnostics closes $75 million financing round

Personal Genome Diagnostics closes $75 million financing round

Personal Genome Diagnostics, a Baltimore-based cancer diagnostics company, has raised $75 million to expand access to genomic testing for cancer patients.

The Series B financing round was led by pharmaceutical giant Bristol-Myers Squibb and existing investor New Enterprise Associates with contributions from Inova Strategic Investments, Co-win Healthcare Fund, Helsinn Investment Fund, Windham Venture Partners and the Maryland Venture Fund.

Douglas Ward, CEO of Personal Genome Diagnostics, or PGDx, described the new funding and test development as an “important next step in our effort to empower the fight against cancer.”

The company specializes in analyzing cancer...

21°